Researchers have discovered a difference between radiation-sensitive and radiation-resistant tumors that could be utilized to assess tumor response, potentially sparing some patients of the toxic side effects of ineffective radiation therapy.
A new microfluidics device has been developed that could detect individual cancer cells in blood and has the potential to be used for liquid biopsies.
Researchers have developed a new diagnostic technique to accurately differentiate bladder cancer from benign inflammation using AHNAK2 protein biomarkers.
Researchers from Syracuse University (NY, USA) have developed a novel class of nanobiosensor that could detect, characterize and analyze protein–protein interactions in blood serum to assist in cancer detection.
Researchers from the University of Queensland (Australia) have discovered a unique biomarker common to multiple cancers that has the potential to change the way early stage cancer is diagnosed.
Researchers at the Brigham Young University (London, UK) have developed a non-invasive, nanoPOTS method for monitoring cancer by measuring the proteins in circulating tumor cells from the blood.
Researchers at the CEU Cardenal Herrera University (Valencia, Spain) have discovered the three most efficient types of salivary biomarkers for the early detection of oral cancer.
Webinar available to view on demand. Thursday 27 September 2018. In this webinar, learn about utilizing xMAP® technology coupled with machine learning algorithms to detect polyps and early-stage colorectal cancer
Time-of-flight secondary ion mass spectrometry utilized in novel technique to map tumor cell signaling
A team from the University of Washington (WA, USA) has demonstrated the use of time-of-flight secondary ion mass spectrometry for mapping tumor cell signals in pancreatic cancer mouse models.
Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.